These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34415224)

  • 1. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain.
    Egeberg A; Danø A; Pedersen MH; Sohrt A; Borg E; Notario J
    J Med Econ; 2021; 24(1):1134-1142. PubMed ID: 34415224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
    Nyholm N; Schnack H; Danø A; Skowron F
    Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis.
    Nyholm N; Danø A; Schnack H; Colombo GL
    Clinicoecon Outcomes Res; 2023; 15():607-619. PubMed ID: 37533798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
    Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
    J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
    Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
    Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
    J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.
    Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn AM; Lowry S; Feldman S; Wu JJ; Armstrong AW
    J Dermatolog Treat; 2022 Mar; 33(2):740-748. PubMed ID: 32602762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
    Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis.
    Udkoff J; Eichenfield LF
    J Drugs Dermatol; 2017 Oct; 16(10):964-970. PubMed ID: 29036249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
    Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
    Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
    Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
    JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.